Yong Yu - 11 Sep 2023 Form 4 Insider Report for GENELUX Corp (GNLX)

Role
VP, Clinical Trial Operations
Signature
/s/ Sean Ryder, Attorney-in-Fact
Issuer symbol
GNLX
Transactions as of
11 Sep 2023
Transactions value $
$0
Form type
4
Filing time
12 Sep 2023, 16:24:29
Previous filing
30 Aug 2023
Next filing
15 Sep 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GNLX Stock Option (right to buy) Award $0 +65K $0.00 65K 11 Sep 2023 Common Stock 65K $22.40 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares shall vest on September 11, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter.